This article was originally published in The Gray Sheet
Executive SummaryFiles 510(k) application with FDA for three expanded polytetrafluoroethylene (ePTFE) synthetic vascular grafts, the Minneapolis firm announces Dec. 8. Once approved, the ePTFE grafts will complement Possis' Perma-Seal silicon elastomer dialysis access graft, approved by FDA in September. No independent distributor has been named for either the Perma-Seal or the ePTFE grafts. Possis retained Salomon Smith Barney in January 1998 to explore selling the entire vascular graft business, but the firm says it will not decide the fate of the division until distributors for the current products have been signed
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.